{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:17:27Z","timestamp":1794889047320,"version":"4.9.1"},"reference-count":41,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,25]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The JULIET phase 2 trial evaluated a single infusion of tisagenlecleucel in adult patients with relapsed\/refractory (r\/r) diffuse large B-cell lymphoma (DLBCL). The objective of the current analysis was to evaluate patient-reported health-related quality of life (HRQoL) with a median follow-up of 19.3 months among patients infused with a single dose of tisagenlecleucel. Patients enrolled were \u226518 years of age with r\/r DLBCL after \u22652 lines of therapy and had either undergone a failed autologous stem cell transplant or were ineligible for the procedure. Two validated HRQoL instruments, Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) and Short Form-36 (SF-36) Health Survey, were used to measure HRQoL at baseline and months 3, 6, 12, and 18. At data cutoff (21 May 2018), 115 patients had received tisagenlecleucel infusion. Among the 99 patients evaluated, overall response rate was 54%, and 40% of patients achieved complete response (CR). Initially, 108 patients completed the HRQoL assessments at baseline, including 57 patients who eventually achieved CR or partial response (PR). Further, 30 and 21 patients in clinical response who completed assessments at baseline also completed assessments at months 12 and 18, respectively. Patients who achieved CR or PR sustained HRQoL improvement in all FACT scores at all time points. SF-36 instruments showed improvement above the minimal clinically important differences on 5 of 8 subscales. Long-term follow-up in the phase 2 JULIET study demonstrated that patients with r\/r DLBCL who respond to tisagenlecleucel therapy had sustained, clinically meaningful improvements in HRQoL. This trial was registered at www.clinicaltrials.gov as #NCT02445248.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019001026","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T19:56:08Z","timestamp":1582142168000},"page":"629-637","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":79,"title":["Patient-reported long-term quality of life after tisagenlecleucel in relapsed\/refractory diffuse large B-cell lymphoma"],"prefix":"10.1182","volume":"4","author":[{"given":"Richard T.","family":"Maziarz","sequence":"first","affiliation":[{"name":"Center for Hematologic Malignancies, Oregon Health and Science University (OHSU) Knight Cancer Institute, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0816-6729","authenticated-orcid":false,"given":"Edmund K.","family":"Waller","sequence":"first","affiliation":[{"name":"Bone Marrow and Stem Cell Transplant Center, Winship Cancer Institute of Emory University, Atlanta, GA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9826-1062","authenticated-orcid":false,"given":"Ulrich","family":"Jaeger","sequence":"first","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Fleury","sequence":"first","affiliation":[{"name":"Maisonneuve-Rosemont Hospital, University of Montreal, Montreal, QC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-4796","authenticated-orcid":false,"given":"Joseph","family":"McGuirk","sequence":"first","affiliation":[{"name":"Department of Blood and Bone Marrow Transplant, The University of Kansas Cancer Center, Kansas City, KS;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9799-9428","authenticated-orcid":false,"given":"Harald","family":"Holte","sequence":"first","affiliation":[{"name":"Department of Oncology, Oslo University Hospital, Oslo, Norway;"},{"name":"K.G. Jebsen Centre for B cell Malignancies, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4335-2554","authenticated-orcid":false,"given":"Samantha","family":"Jaglowski","sequence":"first","affiliation":[{"name":"The James Cancer Hospital and"},{"name":"Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"first","affiliation":[{"name":"Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Bishop","sequence":"first","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine and Comprehensive Cancer Center, University of Chicago, Chicago, IL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1824-2337","authenticated-orcid":false,"given":"Jason R.","family":"Westin","sequence":"first","affiliation":[{"name":"Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8325-9215","authenticated-orcid":false,"given":"Stephan","family":"Mielke","sequence":"first","affiliation":[{"name":"Department of Cellular Therapy and Allogeneic Stem Cell Transplantation (CAST), Karolinska Institutet, Stockholm, Sweden;"},{"name":"Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden;"},{"name":"Center for Allogeneic Stem Cell Transplantation, Department of Internal Medicine II, W\u00fcrzburg University Medical Center, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0941-271X","authenticated-orcid":false,"given":"Takanori","family":"Teshima","sequence":"first","affiliation":[{"name":"Department of Hematology, Hokkaido University Hospital, Sapporo, Japan;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Foley","sequence":"first","affiliation":[{"name":"Juravinski Hospital and Cancer Centre, McMaster University, Hamilton, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"first","affiliation":[{"name":"Department of Haematology and Oncology, University Hospital of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles A.","family":"Salles","sequence":"first","affiliation":[{"name":"Department of Hematology, Centre Hospitalier Lyon-Sud Hospital, Hospices Civils de Lyon, University of Lyon, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"first","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjan","family":"Tiwari","sequence":"first","affiliation":[{"name":"Novartis Healthcare Pvt. Ltd, Hyderabad, India; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7803-2366","authenticated-orcid":false,"given":"Lida B.","family":"Pacaud","sequence":"first","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiufei","family":"Ma","sequence":"first","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Tam","sequence":"first","affiliation":[{"name":"Peter MacCallum Cancer Centre, St Vincent\u2019s Hospital and University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,2,19]]},"reference":[{"issue":"16","key":"2020022511293748100_B1","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood 2018;131(5):587-588]","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"2020022511293748100_B2","unstructured":"Kymriah (tisagenlecleucel) [summary of product characteristics]. Amsterdam, The Netherlands: European Medicines Agency; 2018. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kymriah-epar-product-information_en.pdf. Accessed 3 February 2020."},{"key":"2020022511293748100_B3","unstructured":"Kymriah (tisagenlecleucel) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2018. https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package-Insert---KYMRIAH.pdf. Accessed 3 February 2020."},{"key":"2020022511293748100_B4","unstructured":"Kymriah (tisagenlecleucel) [prescribing information]. Dorval, QC, Canada: Novartis Pharmaceuticals Canada Inc; 2018. https:\/\/pdf.hres.ca\/dpd_pm\/00047683.PDF. Accessed 3 February 2020."},{"key":"2020022511293748100_B5","unstructured":"Oxford Biomedica . Oxford Biomedica notes the Japanese approval of Kymriah\u00ae (tisagenlecleucel), the first CAR-T cell therapy authorised in Asia. 26 March 2019. Oxford, UK: Oxford Biomedica, PLC. https:\/\/www.oxfordbiomedica.co.uk\/news-media\/press-release\/oxford-biomedica-notes-japanese-approval-kymriah%C2%AE-tisagenlecleucel-first. Accessed 3 February 2020."},{"issue":"7","key":"2020022511293748100_B6","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2017-03-737403","article-title":"Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?","volume":"130","author":"Efficace","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2020022511293748100_B7","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2008.03.017","article-title":"Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - a systematic review to evaluate the added value in supporting clinical decision making","volume":"44","author":"Efficace","year":"2008","journal-title":"Eur J Cancer"},{"issue":"1","key":"2020022511293748100_B8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","article-title":"Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes","volume":"273","author":"Wilson","year":"1995","journal-title":"JAMA"},{"key":"2020022511293748100_B9","author":"Maziarz"},{"issue":"1","key":"2020022511293748100_B10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"2020022511293748100_B11","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bjh.12375","article-title":"Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy","volume":"162","author":"Harrison","year":"2013","journal-title":"Br J Haematol"},{"issue":"6","key":"2020022511293748100_B12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"3","key":"2020022511293748100_B13","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1993.11.3.570","article-title":"The Functional Assessment of Cancer Therapy scale: development and validation of the general measure","volume":"11","author":"Cella","year":"1993","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020022511293748100_B14","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/00000421-200112000-00013","article-title":"Validity and reliability of the FACT-G scale for use in the older person with cancer","volume":"24","author":"Overcash","year":"2001","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"2020022511293748100_B15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1477-7525-1-79","article-title":"The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"issue":"12","key":"2020022511293748100_B16","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2446::AID-CNCR23>3.0.CO;2-Q","article-title":"Psychometric analysis of the Functional Assessment of Cancer Therapy-General (FACT-G) scale in a rural sample","volume":"79","author":"Winstead-Fry","year":"1997","journal-title":"Cancer"},{"issue":"15","key":"2020022511293748100_B17","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1200\/JCO.2002.11.017","article-title":"Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"10","key":"2020022511293748100_B18","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","article-title":"Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin\u2019s lymphoma","volume":"20","author":"Witzig","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020022511293748100_B19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/cncr.27781","article-title":"Health-related quality of life among survivors of aggressive non-Hodgkin lymphoma","volume":"119","author":"Jensen","year":"2013","journal-title":"Cancer"},{"issue":"8","key":"2020022511293748100_B20","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.22581","article-title":"Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study","volume":"109","author":"Mols","year":"2007","journal-title":"Cancer"},{"issue":"14","key":"2020022511293748100_B21","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1002\/cncr.24391","article-title":"Health status and quality of life among non-Hodgkin lymphoma survivors","volume":"115","author":"Smith","year":"2009","journal-title":"Cancer"},{"key":"2020022511293748100_B22","author":"Ware","year":"2002"},{"key":"2020022511293748100_B23","author":"Ware","year":"1994"},{"issue":"3","key":"2020022511293748100_B24","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00435226","article-title":"Interpretation of quality of life changes","volume":"2","author":"Lydick","year":"1993","journal-title":"Qual Life Res"},{"issue":"11","key":"2020022511293748100_B25","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2376.2376","article-title":"Validation of the functional assessment of cancer therapy\u2013lymphoma (FACT-LYM) in patients with relapsed\/refractory mantle cell lymphoma [abstract]","volume":"112","author":"Carter","year":"2008","journal-title":"Blood"},{"issue":"2","key":"2020022511293748100_B26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.rmed.2009.09.006","article-title":"The SF-36 and SGRQ: validity and first look at minimum important differences in IPF","volume":"104","author":"Swigris","year":"2010","journal-title":"Respir Med"},{"key":"2020022511293748100_B27","article-title":"Sustained disease control for adult patients with relapsed or refractory diffuse large B-cell lymphoma: An updated analysis of JULIET, a global, pivotal, phase 2 trial of tisagenlecleucel [abstract]","volume-title":"Blood","author":"Schuster","year":"2018"},{"key":"2020022511293748100_B28","first-page":"S181","article-title":"Prolonged improvement in patient reported quality of life following tisagenlecleucel infusion in adult patients with relapsed\/refractory diffuse large B-cell lymphoma: 19-month follow-up of the JULIET study","volume-title":"Biol Blood Bone Marrow Transplant","author":"Tam","year":"2019"},{"issue":"21","key":"2020022511293748100_B29","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.4287.4287","article-title":"Health-related quality of life in older patients following diffuse large B-cell lymphoma (DLBCL) diagnosis [abstract]","volume":"120","author":"Kelly","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2020022511293748100_B30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11195-016-9459-3","article-title":"Changes in sexuality, body image and health related quality of life in patients treated for hematologic malignancies: A longitudinal study","volume":"34","author":"Olsson","year":"2016","journal-title":"Sex Disabil"},{"issue":"3","key":"2020022511293748100_B31","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3109\/10428194.2010.541310","article-title":"Quality of life in patients with diffuse large B-cell lymphoma treated with dose-dense chemotherapy is only affected temporarily","volume":"52","author":"Tholstrup","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2020022511293748100_B32","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/hon.2522","article-title":"Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma","volume":"36","author":"Thompson","year":"2018","journal-title":"Hematol Oncol"},{"issue":"5","key":"2020022511293748100_B33","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00277-013-1980-1","article-title":"Quality of life more impaired in younger than in older diffuse large B cell lymphoma survivors compared to a normative population: a study from the population-based PROFILES registry","volume":"93","author":"van der Poel","year":"2014","journal-title":"Ann Hematol"},{"key":"2020022511293748100_B34","author":"Lenz","year":"2018"},{"issue":"31","key":"2020022511293748100_B35","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"key":"2020022511293748100_B36","author":"Sidana"},{"key":"2020022511293748100_B37","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-111711","article-title":"Patient-reported and neurocognitive outcomes in patients treated with axicabtagene ciloleucel","volume":"132","author":"Jim","year":"2018","journal-title":"Blood"},{"key":"2020022511293748100_B38","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e19052","article-title":"TRANSCEND NHL 001: Health-related quality of life (HRQL) and symptom (Sx) impact in patients (pts) with relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL) receiving lisocabtagene maraleucel (Liso-cel; JCAR017) [abstract]","volume":"37","author":"Patrick","year":"2019","journal-title":"J Clin Oncol"},{"key":"2020022511293748100_B39","author":"Baruchel"},{"issue":"5","key":"2020022511293748100_B40","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.1016\/j.bbmt.2018.11.025","article-title":"Patient-reported outcomes with chimeric antigen receptor T cell therapy: challenges and opportunities","volume":"25","author":"Chakraborty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2020022511293748100_B41","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4065\/77.4.371","article-title":"Methods to explain the clinical significance of health status measures","volume":"77","author":"Guyatt","year":"2002","journal-title":"Mayo Clin Proc"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/4\/629\/1717329\/advancesadv2019001026.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/4\/629\/1717329\/advancesadv2019001026.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,28]],"date-time":"2021-02-28T04:12:55Z","timestamp":1614485575000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/4\/629\/452514\/Patientreported-longterm-quality-of-life-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,19]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019001026","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,19]]}}}